Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NK cells respond to tumors through several activated receptors (e.g natural cytotoxic receptors) or indirectly respond to tumors through activated Fc-receptor common gamma chain (FcRγ) of antibody targeted cells. The activation of NK cell effector functions mediated by Fc-receptor depends on the physically related transmembrane signal transduction adaptors of Fc signaling molecule (such as FcRγ (also known as FcεRIγ)), which are highly expressed by NK cells and participate in NK cell activity. Recently, NK cells lacking FcRγ (called G-NK cells) have been identified as a novel subpopulation of human NK cells, which lack FcRγ (a transmembrane signal translator related to CD16 (Fc receptor for IgG)). These FcRγ-deficient NK cells show significant functional activity on target cells.
At Creative Biolabs, we have established a unique NK cell platform that enables producing FcRγ-deficient NK cells. These engineered NK cells can be utilized as a cell-based "off-the-shelf" treatment for CAR-NK therapy.
In conventional NK cells, the Fc receptor (CD16) of a therapeutic antibody binds to FcRg and/or CD3z signal transduction adapters in homodimer or heterodimer. Differently, CD16 is only related to CD3z in g-NK cells. Compared with traditional NK cells, G-NK cells carry larger granzymes and perforin-containing particles, allowing them to provide a larger payload of lethal enzymes to multiple targets. The ability of cytokine production, the release of cytotoxic granules, safety, mobility, and prolonged survival, and the expansion of g-NK cells have been proven greatly enhanced.
Based on our NK cell platform, we provide this novel subset of NK cells, which are validated with adaptive immune functions, including clonal expansion and long-term persistence. These unique activated NK cells are optimized to retain a wide range of activated receptors while lacking FcRγ receptors, which can selectively target and kill diseased cells.
Fig.1 Schematic illustration of conventional NK and FcRg-deficient (g-NK) cells.
Off-the-Shelf
A universal cell-based therapy that does not require personalized patient matching.
Eliminate a Step
No need to collect the patient's white blood cells. With off-the-shelf G-NK, this invasive procedure is eliminated.
Dosing Control
G-NK's clearance and multiple dosing may reduce the risk of adverse events, thereby producing a favorable safety profile.
Cost Effective
Economical cell therapy treatment for cancer patients G-NK can be produced in large multi-dose batches.
Notably, as the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NK therapy development, including but not limited to:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
